213 related articles for article (PubMed ID: 17992200)
1. Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.
Shashkova EV; Kuppuswamy MN; Wold WS; Doronin K
Cancer Gene Ther; 2008 Feb; 15(2):61-72. PubMed ID: 17992200
[TBL] [Abstract][Full Text] [Related]
2. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
[TBL] [Abstract][Full Text] [Related]
3. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.
Toth K; Tarakanova V; Doronin K; Ward P; Kuppuswamy M; Locke JE; Dawson JE; Kim HJ; Wold WS
Cancer Gene Ther; 2003 Mar; 10(3):193-200. PubMed ID: 12637940
[TBL] [Abstract][Full Text] [Related]
4. Targeting Interferon-α Increases Antitumor Efficacy and Reduces Hepatotoxicity of E1A-mutated Spread-enhanced Oncolytic Adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 28182898
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein.
Doronin K; Toth K; Kuppuswamy M; Ward P; Tollefson AE; Wold WS
J Virol; 2000 Jul; 74(13):6147-55. PubMed ID: 10846098
[TBL] [Abstract][Full Text] [Related]
6. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
7. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
8. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
Zhang R; Zhang X; Ma B; Xiao B; Huang F; Huang P; Ying C; Liu T; Wang Y
Cancer Gene Ther; 2016 Jun; 23(6):168-77. PubMed ID: 27080225
[TBL] [Abstract][Full Text] [Related]
10. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
[TBL] [Abstract][Full Text] [Related]
11. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.
Shim SH; Lee CT; Hun Hah J; Lee JJ; Park SW; Heo DS; Sung MW
Cancer Sci; 2010 Feb; 101(2):482-7. PubMed ID: 19922505
[TBL] [Abstract][Full Text] [Related]
12. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.
Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J
Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303
[TBL] [Abstract][Full Text] [Related]
13. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling.
Toth K; Djeha H; Ying B; Tollefson AE; Kuppuswamy M; Doronin K; Krajcsi P; Lipinski K; Wrighton CJ; Wold WS
Cancer Res; 2004 May; 64(10):3638-44. PubMed ID: 15150123
[TBL] [Abstract][Full Text] [Related]
14. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus.
Zhou W; Zhu H; Chen W; Hu X; Pang X; Zhang J; Huang X; Fang B; He C
Cancer Gene Ther; 2011 May; 18(5):336-45. PubMed ID: 21183948
[TBL] [Abstract][Full Text] [Related]
17. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
Oh E; Hong J; Kwon OJ; Yun CO
Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
[TBL] [Abstract][Full Text] [Related]
18. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.
Zhang X; Komaki R; Wang L; Fang B; Chang JY
Clin Cancer Res; 2008 May; 14(9):2813-23. PubMed ID: 18451249
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.
Jiménez JA; Li X; Zhang YP; Bae KH; Mohammadi Y; Pandya P; Kao C; Gardner TA
Cancer Gene Ther; 2010 Mar; 17(3):180-91. PubMed ID: 19798123
[TBL] [Abstract][Full Text] [Related]
20. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.
Zhou W; Dai S; Zhu H; Song Z; Cai Y; Lee JB; Li Z; Hu X; Fang B; He C; Huang X
Gene Ther; 2017 Apr; 24(4):199-207. PubMed ID: 28075429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]